FindTrial
Sign In

A dose finding study of KRN125

A dose finding study of KRN125 for chemotherapy-induced neutropenia in malignant lymphoma

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220851
Enrollment
Unknown
Registered
2009-09-09
Start date
2009-09-09
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapy-induced neutropenia

Interventions

investigational material(s) Generic name etc : KRN125 INN of investigational material : Therapeutic category code : 339 Other agents relating to blood and body fluides Dosage and Administration for I

Sponsors

Kyowa Hakko Kirin Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Diagnosed with Hodgkin's or non-Hodgkin's lymphoma Going to receive CHASE treatment regimen ECOG PS =< 2 Appropriate bone marrow, hepatic and renal functions Written informed consent

Exclusion criteria

Exclusion criteria: Double cancer Previous bone marrow or peripheral blood stem cell transplant More than 3 prior chemotherapies for salvage treatment regimen Primary hematologic disease such as myelodysplastic syndrome, aplastic anemia, or sickle cell disease Undergoing interstitial pneumonia treatment Previous radiotherapy within 4 weeks of enrollment

Design outcomes

Primary

MeasureTime frame
Efficacy: duration of severe neutropenia—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026